For virologically suppressed adults with HIV-1. See Full Indication.

Clinical Trials for CABENUVA

CABENUVA has been studied extensively in two robust, Phase 3, clinical trials: ATLAS and FLAIR. The findings from these studies for once-monthly CABENUVA laid the foundation for ATLAS-2M, a large, Phase 3b noninferiority study comparing once-monthly CABENUVA to every-2-month CABENUVA1. Click on the respective links below to view the data.

Chart Icon

Once-Monthly CABENUVA Clinical Trials

See the results of 2 Phase 3 clinical trials, ATLAS and FLAIR, that evaluated once-monthly, long-acting CABENUVA vs continuing daily oral ARV therapy

Chart Icon

Every-2-Month CABENUVA Clinical Trial

View data from ATLAS-2M, a Phase 3b clinical trial comparing once-monthly CABENUVA to every-2-month CABENUVA

ARV=antiretroviral.

Reference:

  1. CABENUVA [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2021.

CBRWCNT210051